Medical Meetings

Learn about the latest myeloma research. Get a front row seat at the most critical medical meetings. Watch Dr. Brian Durie, IMF Chairman, address issues that are important to the entire myeloma community. IMF TV brings it all to you.

Jul
13
Myeloma Updates 2017: Best of ASCO/EHA/IMWG
Dr. Brian G.M. Durie explains the new and exciting current trends in myeloma treatment and research with this update from the three major medical meetings held in June 2017 – the American Society of(...)
Jun
06
Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients with relapsed or refractory multiple myeloma: Subgroup analysis of POLLUX and CASTOR
Saad Z. Usmani, MD Levine Cancer Institute Carolinas HealthCare System Charlotte, NC Background: Daratumumab (D) plus lenalidomide and dexamethasone (Rd; POLLUX) or with bortezomib and dexamethasone(...)
Jun
06
Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001)
Adrzej J. Jakubowiak, MD University of Chicago Medical Center Chicago, IL, USA Background: DARA in combination with established standard of care regimens prolongs PFS, deepens responses, and(...)
Jun
06
The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma
Wilson I. Gonsalves, MD Mayo Clinic Rochester, MN, USA Background: Human adipocytes can contribute directly to the in vitro growth and progression of multiple myeloma (MM) cell lines. Clinically, an(...)
Jun
05
Impact of denosumab compared with zoledronic acid on renal function in the treatment of myeloma bone disease
Noopur S. Raje, MD Massachusetts General Hospital Cancer Center Boston, MA Background: Osteolytic bone disease and renal dysfunction are complications of multiple myeloma. ZA, used for the prevention(...)
Jun
05
A phase Ib study of isatuximab in combination with pomalidomide and dexamethasone in RRMM
Joseph Mikhael, MD Mayo Clinic Phoenix, AZ, USA Background: Isatuximab (ISA) is an anti-CD38 monoclonal antibody, which kills tumor cells via multiple mechanisms. Here, we report preliminary data(...)